Ad
Monday, 27 March 2017
Mylan underpayment on EpiPen could exceed proposed settlement -study
NEW YORK (Reuters) - The amount that drugmaker Mylan NV avoided paying the U.S. government in Medicaid rebates for its EpiPen emergency allergy treatment since 2007 likely exceeds a proposed $465 million settlement the company announced in October, according to a study by private drug pricing experts published on Monday.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment